NewEdge Advisors LLC Increases Stake in Eli Lilly and Company $LLY

Key Points

• NewEdge Advisors increased its Eli Lilly stake by 5.8% in the second quarter, adding 10,626 shares to hold 194,721 shares valued at approximately $233.6 million. Institutional investors collectively own 82.53% of LLY.
• Eli Lilly reported a strong quarter, with adjusted EPS of $8.38 beating estimates by $1.98 and revenue rising 47.7% year over year to $22.97 billion. The company set fiscal 2026 EPS guidance at $35.50–$36.50 and maintains a $1.73 quarterly dividend.
• Analysts remain broadly positive, with a consensus “Moderate Buy” rating and an average price target of $1,295.39, although investors continue to weigh Lilly’s high valuation, competition, supply constraints and the challenge of sustaining rapid GLP-1-driven growth.

NewEdge Advisors LLC increased its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 5.8% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 194,721 shares of the company's stock after acquiring an additional 10,626 shares during the quarter. Eli Lilly and Company makes up about 0.7% of NewEdge Advisors LLC's investment portfolio, making the stock its 25th largest position. NewEdge Advisors LLC's holdings in Eli Lilly and Company were worth $233,555,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in LLY. Brighton Jones LLC raised its stake in Eli Lilly and Company by 22.0% in the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company's stock worth $7,409,000 after buying an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC boosted its position in Eli Lilly and Company by 2.8% during the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company's stock valued at $1,136,000 after purchasing an additional 40 shares in the last quarter. Schnieders Capital Management LLC. boosted its position in Eli Lilly and Company by 16.7% during the second quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company's stock valued at $6,231,000 after purchasing an additional 1,141 shares in the last quarter. Flow Traders U.S. LLC purchased a new position in Eli Lilly and Company in the second quarter valued at about $356,000. Finally, Nebula Research & Development LLC bought a new position in Eli Lilly and Company in the second quarter worth about $749,000. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Price Performance

Shares of LLY stock opened at $1,122.74 on Friday. Eli Lilly and Company has a fifty-two week low of $712.05 and a fifty-two week high of $1,292.65. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. The firm has a market capitalization of $1.06 trillion, a price-to-earnings ratio of 37.68, a PEG ratio of 1.39 and a beta of 0.50. The stock's 50-day simple moving average is $1,185.52 and its 200-day simple moving average is $1,072.89.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, topping analysts' consensus estimates of $6.40 by $1.98. The company had revenue of $22.97 billion during the quarter, compared to analysts' expectations of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. Eli Lilly and Company's revenue for the quarter was up 47.7% on a year-over-year basis. During the same period last year, the business earned $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, equities analysts forecast that Eli Lilly and Company will post 36.35 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, September 10th. Investors of record on Friday, August 14th were given a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend was Friday, August 14th. Eli Lilly and Company's dividend payout ratio is presently 23.22%.

Insider Buying and Selling

In other news, CAO Donald A. Zakrowski sold 2,000 shares of the stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the transaction, the chief accounting officer directly owned 1,526 shares of the company's stock, valued at approximately $1,808,325.26. This represents a 56.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the sale, the executive vice president directly owned 11,875 shares of the company's stock, valued at $14,131,250. This trade represents a 29.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 13,500 shares of company stock worth $15,958,170 in the last 90 days. Insiders own 0.14% of the company's stock.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly’s GLP-1 franchise is described as growing at nearly 50% annually, supporting the company’s recent rise above a $1 trillion market capitalization. Analysts and commentators continue to see attractive medium-term prospects from strong demand for obesity and diabetes treatments. Eli Lilly Stock Has Become a Trillion-Dollar Giant
• Positive Sentiment: Coverage highlights Lilly’s broadening pipeline, with profits from incretin drugs helping fund development of the next generation of medicines. The company is also expected to use GLP-1 proceeds to expand into women’s health, potentially creating additional long-term growth avenues. Eli Lilly’s pipeline in 2026
• Positive Sentiment: Reports that Lilly rationed some launches because demand exceeded supply underscore the commercial strength of its products, although they also highlight the importance of expanding manufacturing capacity. What Eli Lilly Was Telling You While It Rationed Its Own Launches
• Neutral Sentiment: Articles comparing Lilly with Nvidia and projecting the value of long-term investments remain favorable toward Lilly’s growth story, but they are opinion pieces and do not introduce a new near-term earnings catalyst. Got $10,000? Eli Lilly vs. Nvidia
• Negative Sentiment: Investors are increasingly focused on whether Lilly’s valuation already reflects much of its GLP-1 success. The recent pullback and concerns about competition, supply, pipeline execution and the difficulty of sustaining rapid growth may be limiting upside and weighing on the stock. Eli Lilly Stock Has Become a Trillion-Dollar Giant

Analysts Set New Price Targets

Several research firms have commented on LLY. Bank of America increased their price target on shares of Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the company a "buy" rating in a research report on Friday, July 10th. Berenberg Bank lifted their price objective on shares of Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the stock a "hold" rating in a research report on Monday, June 22nd. Guggenheim boosted their price objective on shares of Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the stock a "buy" rating in a research note on Monday, July 13th. Cantor Fitzgerald increased their target price on shares of Eli Lilly and Company from $1,350.00 to $1,410.00 and gave the company an "overweight" rating in a research report on Thursday, August 6th. Finally, Wells Fargo & Company raised their target price on shares of Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the company an "overweight" rating in a research note on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $1,295.39.

Eli Lilly and Company Profile

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its portfolio includes treatments for diabetes and obesity, oncology, immunology, neuroscience, cardiovascular disease and other areas of significant unmet medical need.

The company's products include Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, and insulin products such as Humalog. Lilly also markets Verzenio for certain breast cancers and Kisunla for the treatment of early symptomatic Alzheimer's disease.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.